CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+30.05%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$647M
AUM Growth
+$647M
(+0.35%)
Cap. Flow
-$87.5M
Cap. Flow
% of AUM
-13.52%
Top 10 Holdings %
Top 10 Hldgs %
48.48%
Holding
75
New
6
Increased
14
Reduced
49
Closed
4
Top Buys
| 1 |
Alkermes
ALKS
|
$15.2M |
| 2 |
Bristol-Myers Squibb
BMY
|
$13.5M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$13.3M |
| 4 |
Heron Therapeutics
HRTX
|
$8.29M |
| 5 |
PFNX
Pfenex Inc.
PFNX
|
$7.57M |
Top Sells
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$41.5M |
| 2 |
CELG
Celgene Corp
CELG
|
$33.6M |
| 3 |
Puma Biotechnology
PBYI
|
$12.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$11.2M |
| 5 |
Tempest Therapeutics
TPST
|
$9.87M |
Sector Composition
| 1 | Healthcare | 72.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $64.4M | 9.95% | 390,312 -251,488 | -39% | -$41.5M |
|
|
2
Alkermes
ALKS
$4.78B
| $42.7M | 6.6% | 700,000 +250,000 | +56% | +$15.2M |
|
|
3
Puma Biotechnology
PBYI
$254M
| $39.5M | 6.1% | 167,300 -52,700 | -24% | -$12.4M |
|
|
EGRX
4
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $30M | 4.64% | 716,500 +316,500 | +79% | +$13.3M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $29.6M | 4.58% | 459,000 +209,000 | +84% | +$13.5M |
|
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $28.5M | 4.41% | 718,900 -281,100 | -28% | -$11.2M |
|
|
PTLA
7
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $21.8M | 3.37% | 574,500 -25,500 | -4% | -$968K |
|
|
SRNE
8
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $19.1M | 2.95% | 1,652,912 -97,088 | -6% | -$1.12M |
|
|
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
| $19.1M | 2.95% | 1,138,900 -361,100 | -24% | -$6.05M |
|
|
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $19M | 2.94% | 1,119,100 +19,100 | +2% | +$325K |
|
|
11
Heron Therapeutics
HRTX
$207M
| $18.5M | 2.86% | 1,270,000 +570,000 | +81% | +$8.29M |
|
|
12
Tempest Therapeutics
TPST
$44M
| $16.1M | 2.48% | 462,720 -284,280 | -38% | -$9.87M |
|
|
RGLS
13
DELISTED
Regulus Therapeutics
RGLS
| $15.2M | 2.35% | 896,522 -203,478 | -18% | -$3.45M |
|
|
ADXS
14
DELISTED
Advaxis, Inc.
ADXS
| $14.1M | 2.18% | 975,375 +135,875 | +16% | +$1.96M |
|
15
Ardelyx
ARDX
$1.53B
| $13.3M | 2.05% | 1,013,785 -39,715 | -4% | -$520K |
|
|
TSRO
16
DELISTED
TESARO, Inc.
TSRO
| $11M | 1.7% | 191,250 -108,750 | -36% | -$6.24M |
|
|
KERX
17
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $10.5M | 1.62% | 826,000 -174,000 | -17% | -$2.22M |
|
18
Novavax
NVAX
$1.21B
| $10.2M | 1.58% | 1,238,300 -261,700 | -17% | -$2.16M |
|
19
DexCom
DXCM
$29.5B
| $9.54M | 1.47% | 153,000 -47,000 | -24% | -$2.93M |
|
20
Karyopharm Therapeutics
KPTI
$61.7M
| $9.21M | 1.42% | 300,987 -84,013 | -22% | -$2.57M |
|
|
ALDR
21
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $9.16M | 1.42% | 317,475 +67,475 | +27% | +$1.95M |
|
|
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
| $8.65M | 1.34% | 229,500 -170,500 | -43% | -$6.43M |
|
23
Omeros
OMER
$283M
| $8.56M | 1.32% | 388,500 -193,800 | -33% | -$4.27M |
|
|
EPRS
24
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $8.03M | 1.24% | 896,600 +821,600 | +1,095% | +$7.35M |
|
|
PFNX
25
DELISTED
Pfenex Inc.
PFNX
| $7.57M | 1.17% | +474,900 | New | +$7.57M |
|